A5105299009- Peripheral Neuropathies and Disorders
- Autoimmune Neurological Disorders and Treatments
- Neurological and metabolic disorders
- Sarcoidosis and Beryllium Toxicity Research
- Vasculitis and related conditions
- Polyomavirus and related diseases
- Cerebrospinal fluid and hydrocephalus
- HIV Research and Treatment
- HIV-related health complications and treatments
- IgG4-Related and Inflammatory Diseases
- Infectious Diseases and Tuberculosis
- Infectious Encephalopathies and Encephalitis
- Parasitic infections in humans and animals
- Neurological disorders and treatments
- Retinal and Optic Conditions
- Peripheral Nerve Disorders
- Traumatic Brain Injury and Neurovascular Disturbances
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Genetic Neurodegenerative Diseases
- Ocular Diseases and Behçet’s Syndrome
- Cytomegalovirus and herpesvirus research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Multiple Sclerosis Research Studies
- Plant Virus Research Studies
- Parasites and Host Interactions
Massachusetts General Hospital
2016-2025
Harvard University
2011-2024
Neurology, Inc
2021
Massachusetts Institute of Technology
2019
University of Pennsylvania
2019
University of Iowa
2019
Brigham and Women's Hospital
2015-2018
University of Illinois Chicago
2018
Washington University in St. Louis
2007-2017
Vanderbilt University Medical Center
2017
To describe clinical and imaging responses in neurosarcoidosis to infliximab, a monoclonal antibody against tumor necrosis factor-α.Investigators at 6 US centers retrospectively identified patients with CNS sarcoidosis treated including only definite or probable following rigorous exclusion of other causes.Of 66 (27 definite, 39 probable) infliximab for median 1.5 years, the mean age was 47.5 years initiation (SD 11.7, range 24-71 years); 56.1% were female; 62.1% white, 37.0% African...
<h3>Objective</h3> To characterize the risk factors, clinical course, and treatment of patients with progressive multifocal leukoencephalopathy (PML) diagnosed followed over a 25-year epoch at 2 academic hospitals. <h3>Methods</h3> Patients definite diagnosis PML were identified by positive CSF PCR for JC virus or histopathology between January 1, 1994, 2019. Demographic PML-specific variables recorded on symptomatic presentation follow-up, including outcome, neuroimaging findings, modified...
To determine if changes in brain metabolites are observed during early HIV infection and correlate these with immunologic alterations.Eight subjects infection, 9 HIV-seronegative controls, 10 chronically HIV-infected without neurologic impairment underwent 1H magnetic resonance spectroscopy. Subjects stage were identified near the time of seroconversion imaged within 60 days an evolving Western blot, while still having detectable plasma virus. had blood drawn for viral RNA T cell...
Background: Cerebrospinal fluid (CSF) viral escape is an increasingly recognized clinical event among HIV-1-infected adults. We analyzed longitudinal data and drug-resistance mutations to characterize profiles of patients on antiretroviral therapy with discordant CSF plasma HIV-1 RNA levels. Methods: Forty-one cases defined as detectable when levels were undetectable, or >0.5-log higher in than identified from Boston Hospitals National NeuroAIDS Tissue Consortium (NNTC) 2005 2016....
ABSTRACT JC virus (JCV)-specific CD8 + cytotoxic T lymphocytes (CTL) are associated with a favorable outcome in patients progressive multifocal leukoencephalopathy (PML) and cross-recognize the polyomavirus BK (BKV). We sought to determine frequency phenotype fresh blood of cells specific for two A*0201-restricted JCV epitopes, VP1 p36 p100 , assess their impact on viremia viruria 15 healthy subjects, eight human immunodeficiency virus-positive (HIV ) individuals, nine HIV PML patients)...
<h3>BACKGROUND AND PURPOSE:</h3> There are no validated imaging criteria for the diagnosis of progressive multifocal leukoencephalopathy in cerebellum. Here we introduce MR shrimp sign, a cerebellar white matter lesion identifiable patients with leukoencephalopathy, and evaluate its sensitivity specificity. <h3>MATERIALS METHODS:</h3> We first identified seen at Massachusetts General Hospital between 1998 2019 whose radiology reports included term "cerebellum." Drawing on priori knowledge, 2...
• Three patients had recurrent focal motor seizures as the first manifestation of nonketotic hyperglycemia (NKHG) diabetes mellitus. The were characterized by stereotypical tonic changes in body posture and arrest speech that have been associated with supplementary area seizures. Recognition link between this unusual form epilepsy NKHG would help early diagnosis treatment serious underlying metabolic disturbance.
Retinal vasculopathy with cerebral leukodystrophy (RVCL) is a rare, autosomal dominant condition caused by mutations of TREX1 (3-prime repair exonuclease-1). The phenotypic expressions range from isolated retinal involvement to varying degrees retinopathy, infarction calcium depositions, nephropathy, and hepatopathy. We report case RVCL novel mutation. This patient's multisystem presentation, interpreted as "retinal vasculitis," improvement neuroimaging abnormalities dexamethasone led the...
IgG4-related disease-associated hypertrophic pachymeningitis (IgG4RD-HP) is a fibroinflammatory autoimmune disorder in which diagnosis difficult without biopsy. Guidance on management of disease refractory to glucocorticoids and intravenous rituximab limited. We present the case 68-year-old woman with IgG4RD-HP who developed sensorineural hearing loss associated bulky basilar pachymeningeal enhancement. Her cerebrospinal fluid was inflammatory had an elevated IgG4 concentration, strongly...
We present two cases of recurrent progressive multifocal leukoencephalopathy (PML) in patients with long standing virally suppressed human immunodeficiency virus (HIV) and normal CD4+ T cell count who were taking stable regimens highly active antiretroviral therapy (HAART). This has significant implications for other a past history PML, not just those HIV but also on medications such as natalizumab or fumarates.
Abstract Background Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic neurological condition characterized by progressive myelopathic symptoms including spasticity, pain, weakness, and urinary symptoms, without proven treatments. Mogamulizumab (MOG) monoclonal antibody that binds CCR4 leads to the clearance of HTLV-1-infected CCR4+ cells. A phase 1-2a study in Japan evaluated MOG for treatment HAM/TSP reported decreases...